M&A / Deals Alzheimer’s biotech Korsana to go public via reverse merger PharmaphorumBy merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.M&A / DealsNeuroscienceRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaphorum By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer’s. M&A / DealsNeuroscienceRead full story Post navigation Previous: Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assetsNext: Merck KGaA acquires JSR chromatography business Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
